MDS patients diagnosed according to standard French-American-British criteria received a loading dose of 0.3 mg/kg per day of arsenic trioxide for 5 days followed by a maintenance dose of 0.25 mg/kg ...
Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor–Modified T Cells After Failure of Ibrutinib The Children’s Oncology Group AAML0631 ...
The appraisal committee considered evidence submitted by Teva and a review of this submission by the evidence review group (ERG). See the committee papers for full details of the evidence. Acute ...
You have full access to this article via your institution. As illustrated in Table 1, none of the routine baseline clinical or laboratory parameters were predictive of the subsequent development of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback